fbpx

YOUR GUIDE TO STAYING INFORMED IN THE MARKETS

Subscribe for FREE Email Updates & Access To EXCLUSIVE Research!

Johnson & Johnson’s Executive VP, General Counsel Michael Ullmann To Retire – $JNJ $DIA

By John F. Heerdink, Jr.
LinkedIn Twitter Disclaimer

Reportedly, Johnson & Johnson (JNJ) announced the retirement of Michael Ullman, Executive VP, General Counsel at the end of this year with 33 years of leadership and service to the Company. Effective October 17, 2022, Ullmann will be succeeded by Elizabeth (Liz) Forminard having an exceptional experience across the Company’s Pharmaceutical, MedTech, and Consumer Health sectors. 

“I’m thrilled to appoint Liz to this important role and will lean on her strong business acumen and understanding of patient and customer needs during this pivotal time at our Company. I’m confident her distinguished experience and leadership will help us find new pathways to bring innovative healthcare solutions to those in need all over the world,” stated Joaquin Duato, Chief Executive Officer, Johnson & Johnson. 

In 1989, Mr. Ullmann joined Johnson & Johnson as a mergers & acquisitions attorney and has served in the Company’s Law Department and held positions of increasing responsibility in the Company’s Law Department, for the past eleven years he has been serving as General Counsel.

Liz Forminard has been with Johnson & Johnson for 16 years, having served as General Counsel across each of the Pharmaceutical, Consumer Health, and MedTech sectors, as well as Worldwide Vice President leading the Corporate Governance function, and numerous other functional and business-facing roles during this time.


Dow 30 component Johnson & Johnson (JNJ) is a worldwide healthcare-focused company that embraces research and science so that it can provide customers with innovative ideas, products, and services. To learn more about Johnson & Johnson (JNJ) and to continue to track its progress visit the Vista Partners Johnson & Johnson Coverage Page.

If you liked this story please consider, visiting the Atossa Therapeutics (ATOS) dedicated page at Vista Partners to learn about the Seattle-based biotech firm’s work towards finding therapeutic treatments for Breast Cancer and the Coronavirus. 


Vista Partners LLC (”Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: www.vistapglobal.com with daily stories, weekly market updates, monthly macroeconomic newsletters, podcasts, & Vista’s proprietary equity and market research to help you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also seeks to provide select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives.

Stay Informed! Stay Competitive! Please join us at Vista Partners, receive our FREE email updates throughout the week, and view our exclusive content and research.

(Read Original Story: Johnson & Johnson’s Executive Vice President, General Counsel Michael Ullmann to Retire; Elizabeth Forminard Named General Counsel, Effective October 17, 2022 in Business Wire)